Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643
This examiner grants 57% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17934996 | PROTEIN NANOPARTICLES AND COMBINATION THERAPY FOR CANCER IMMUNOTHERAPY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17775198 | IDENTIFICATION OF SPLICING-DERIVED ANTIGENS FOR TREATING CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18156744 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | Non-Final OA | Genentech, Inc. |
| 17920461 | DUOCARMYCIN DERIVATIVE AND USE THEREOF | Non-Final OA | TOHOKU UNIVERSITY |
| 17054312 | PROXIMITY INDUCED SITE-SPECIFIC ANTIBODY CONJUGATION | Non-Final OA | William Marsh Rice University |
| 18367446 | METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 17262590 | EFFECTIVE METHOD FOR MANUFACTURING ANTIBODY-DRUG CONJUGATE | Non-Final OA | DAIICHI SANKYO COMPANY, LIMITED |
| 17058838 | TREATMENT OF HER2-MUTATED CANCER BY ADMINISTERING ANTI-HER2 ANTIBODY-DRUG CONJUGATE | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 17290797 | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE | Non-Final OA | Thomas Jefferson University |
| 18651929 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | Non-Final OA | UNIVERSITY OF SOUTHAMPTON |
| 18694931 | ANTI-CANCER VACCINE COMPOSITION COMPRISING PEPTIDES DERIVED FROM TUMOR-ASSOCIATED ANTIGEN, AND ADJUVANT CONSISTING OF LIPOPEPTIDE AND IMMUNOACTIVE SUBSTANCE, AND USE THEREOF | Non-Final OA | CHA VACCINE RESEARCH INSTITUTE CO., LTD |
| 18345511 | Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA | Non-Final OA | Bavarian Nordic A/S |
| 18269996 | HUMAN ANTI-TAU ANTIBODIES | Non-Final OA | Neurimmune AG |
| 18269942 | IMMUNE- STIMULATING COMPOUNDS LINKED TO GLYCOGEN-BASED POLYSACCHARIDE NANOPARTICLES FOR SENSITIZING CANCER CELLS TO A CHEMOTHERAPEUTIC DRUG | Non-Final OA | GLYSANTIS BIOTECH INC. |
| 17927501 | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | Non-Final OA | Cue Biopharma, Inc. |
| 18156748 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | Final Rejection | Hangzhou DAC Biotech Co., Ltd. |
| 17423843 | FORMULATIONS | Non-Final OA | IMMUNOCORE LIMITED |
| 18049711 | ANTIBODY DRUG CONJUGATE FOR ANTI-INFLAMMATORY APPLICATIONS | Final Rejection | Ambrx, Inc. |
| 17263258 | CANCER VACCINES FOR UTERINE CANCER | Non-Final OA | CureVac Netherlands B.V. |
| 17262999 | ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER | Final Rejection | CureVac Netherlands B.V. |
| 15734445 | TUMOR MICROENVIRONMENT-ACTIVATED DRUG-BINDER CONJUGATES, AND USES RELATED THERETO | Final Rejection | Avacta Life Sciences, Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy